- Home
- NXT vs MRNA Comparison
NXT vs MRNA Comparison
Compare NXT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXT
- MRNA
- Stock Information
- Founded
- NXT 2013
- MRNA 2010
- Country
- NXT United States
- MRNA United States
- Employees
- NXT N/A
- MRNA N/A
- Industry
- NXT Semiconductors
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXT Technology
- MRNA Health Care
- Exchange
- NXT Nasdaq
- MRNA Nasdaq
- Market Cap
- NXT 10.2B
- MRNA 9.8B
- IPO Year
- NXT 2023
- MRNA 2018
- Fundamental
- Price
- NXT $76.97
- MRNA $27.38
- Analyst Decision
- NXT Buy
- MRNA Hold
- Analyst Count
- NXT 19
- MRNA 17
- Target Price
- NXT $65.58
- MRNA $42.40
- AVG Volume (30 Days)
- NXT 2.0M
- MRNA 12.1M
- Earning Date
- NXT 10-23-2025
- MRNA 11-06-2025
- Dividend Yield
- NXT N/A
- MRNA N/A
- EPS Growth
- NXT N/A
- MRNA N/A
- EPS
- NXT 3.67
- MRNA N/A
- Revenue
- NXT $3,103,529,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- NXT $15.37
- MRNA N/A
- Revenue Next Year
- NXT $9.58
- MRNA $9.75
- P/E Ratio
- NXT $21.13
- MRNA N/A
- Revenue Growth
- NXT 13.26
- MRNA N/A
- 52 Week Low
- NXT $30.93
- MRNA $23.15
- 52 Week High
- NXT $80.83
- MRNA $60.65
- Technical
- Relative Strength Index (RSI)
- NXT 61.83
- MRNA 56.40
- Support Level
- NXT $74.91
- MRNA $23.91
- Resistance Level
- NXT $80.82
- MRNA $28.99
- Average True Range (ATR)
- NXT 3.41
- MRNA 1.22
- MACD
- NXT 0.26
- MRNA 0.38
- Stochastic Oscillator
- NXT 70.74
- MRNA 67.03
About NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.